Consolidated statements of income and comprehensive income
(unaudited)
|
Three months ended 31 March |
|
(thousands of €, except per share data) |
2019 |
2018 |
Revenues |
33,047 |
37,907 |
Other income |
7,872 |
6,931 |
Total revenues and other income |
40,919 |
44,838 |
|
|
|
Research and development expenditure |
(83,195) |
(69,765) |
General and administrative expenses |
(9,221) |
(6,697) |
Sales and marketing expenses |
(1,746) |
(413) |
Total operating expenses |
(94,161) |
(76,875) |
|
|
|
Operating loss |
(53,242) |
(32,036) |
|
|
|
Financial income |
6,999 |
1,610 |
Financial expenses |
(2,345) |
(6,794) |
|
|
|
Loss before tax |
(48,588) |
(37,221) |
|
|
|
Income taxes |
(68) |
(62) |
|
|
|
Net loss |
(48,656) |
(37,283) |
Net loss attributable to: |
|
|
Owners of the parent |
(48,656) |
(37,283) |
Basic and diluted loss per share |
(0.89) |
(0.73) |
The accompanying notes form an integral part of these condensed consolidated financial statements.
|
Three months ended 31 March |
|
(thousands of €) |
2019 |
2018 |
Net loss |
(48,656) |
(37,283) |
Items that may be reclassified subsequently to profit or loss: |
|
|
Translation differences, arisen from translating foreign activities |
267 |
(3) |
Other comprehensive income / loss (-), net of income tax |
267 |
(3) |
|
|
|
Total comprehensive income / loss (-) attributable to: |
|
|
Owners of the parent |
(48,389) |
(37,286) |
The accompanying notes form an integral part of these condensed consolidated financial statements.